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Summary 9 
Oral rotavirus vaccines have consistently underperformed in low-income countries. In this issue of 10 
Cell Host & Microbe, Harris et al (2018) explore whether vaccine response can be enhanced via 11 
antibiotic-mediated modification of the bacterial microbiota. 12 
 13 
Full text 14 
Diarrheal disease currently claims the lives of approximately 500,000 children each year. Although 15 
a range of intestinal pathogens contribute to this, rotavirus accounts for more severe cases and 16 
hospitalizations than any other. Globally, the virus is responsible for more than a third of diarrhea-17 
associated deaths in children under 5 years of age. 18 
 Over the past decade, the burden of rotavirus disease has been gradually eroded by the roll-out 19 
of oral rotavirus vaccines, which have now been introduced in more than 90 countries. Yet current 20 
rotavirus vaccines have a crucial weakness – they are less effective precisely where they are needed 21 
most. Whereas more than 95% of infants in high-income countries are protected from severe 22 
rotavirus disease in the year following vaccination, protection is diminished in low- and middle-23 
income countries, falling shy of 50% in parts of sub-Saharan Africa (Madhi et al., 2010). Thus, 24 
despite vaccine coverage of over 80% in many countries, rotavirus may remain the leading cause of 25 
hospitalized gastroenteritis (Platts-Mills et al., 2017). 26 
This phenomenon is unlikely to have a simple explanation or a simple solution. Maternal 27 
antibodies, viral co-infections, and histo-blood group antigen genotype may all contribute to the 28 
impaired efficacy of oral vaccines in low-income countries (Parker et al., 2018a). In addition, the 29 
bacterial microbiota has been singled out as a potentially significant contributor. Indeed, microbiota 30 
composition is known: (i) to vary by geographic setting from an early age; (ii) to be important for the 31 
development of the mucosal immune system (Ruiz et al., 2017); and (iii) to influence the replication 32 
and immunogenicity of intestinal viruses, including rotavirus, in mice (Uchiyama et al., 2014).  33 
To date, three observational studies have attempted to characterize the association between 34 
bacterial microbiota composition and rotavirus vaccine response. Among infants in Ghana (n = 68), 35 
immune response following two doses of the monovalent vaccine Rotarix was reported to be 36 
negatively correlated with relative abundance of the bacterial phylum Bacteroidetes and positively 37 
correlated with abundance of the class Bacilli at the time of the first vaccine dose (Harris et al., 2016). 38 
However, these taxonomic associations were not evident during a smaller study in Pakistan (n = 20) 39 
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(Harris et al., 2017). Instead, several distinct associations were highlighted, including a higher 40 
abundance of the phylum Proteobacteria in Rotarix responders. Finally, among infants in India (n = 41 
170), there were no significant differences in the composition of the bacterial microbiota between 42 
rotavirus vaccine responders and non-responders after statistical correction for multiple comparisons 43 
(Parker et al., 2018b).  44 
What should we make of these findings? On the one hand, they hint at several intriguing 45 
associations between microbiota composition and rotavirus vaccine response. On the other hand, 46 
the picture varies from study to study, and reproducible predictors of vaccine response across 47 
different geographic settings remain elusive. Additional studies exploring the link between 48 
microbiome composition and rotavirus vaccine response are likely to accumulate in the coming 49 
years, and may shed further light on this relationship.  50 
If robust associations between microbiota composition and rotavirus vaccine response can be 51 
found, a crucial question will remain: can the microbiota be modified to improve vaccine efficacy? In 52 
this issue of Cell Host & Microbe, Harris et al (2018) report on a proof-of-concept study exploring 53 
this question. Specifically, the authors set out to test whether recapitulating some of the microbiota 54 
phenotypes that correlated with vaccine response in previous observational studies might improve 55 
rotavirus vaccine performance. The study included three arms, each containing 21 Dutch adults. In 56 
one arm, individuals received a 7-day course of oral vancomycin, an antibiotic that has been shown 57 
to deplete the relative abundance of Bacteroidetes while increasing the abundance of Proteobacteria 58 
(Isaac et al., 2017). In the second arm, the adults received a 7-day course of broad-spectrum 59 
antibiotics (oral vancomycin, ciprofloxacin, and metronidazole), aiming to induce a more extensive 60 
and indiscriminate depletion of the bacterial microbiota. In the third arm, individuals received 61 
placebo. Three days after completing treatment, all adults received a single dose of Rotarix. Vaccine 62 
immunogenicity was determined by measuring the titer of rotavirus-specific antibodies before 63 
treatment and 7, 14, and 28 days after vaccination. The presence of rotavirus in stool was also 64 
measured in the week after vaccination to provide an indicator of vaccine virus replication (‘take’). 65 
As expected, antibiotic treatment induced marked perturbations in microbiota composition 66 
(determined by sequencing the bacterial 16S rRNA gene in stool samples). In both treatment arms, 67 
a significant reduction in microbiota diversity was seen at the time of vaccination. At phylum level, 68 
vancomycin induced a depletion in the relative abundance of Bacteroidetes and Firmicutes alongside 69 
a pronounced increase in Proteobacteria. Broad-spectrum antibiotics induced similar changes, albeit 70 
without the bloom in Proteobacteria. 71 
There was no strong impact of treatment on the immune response to vaccination. Rotavirus-72 
specific IgA titers did not differ between study arms 28 days after vaccination (the primary outcome 73 
of the trial), nor at any other timepoint. Only 2/63 (3%) of individuals exhibited a 4-fold rise in IgA 74 
titer at 28 days (a common immunogenicity measure in rotavirus vaccine trials). The authors did 75 
observe the ‘boosting’ of rotavirus-specific antibodies (defined as a 2-fold increase in IgA titer) to be 76 
more frequent in vancomycin recipients at day 7 (8/21 vs 1/21 in the other arms); however, this effect 77 
was not apparent at days 14 or 28 and is of equivocal significance given the multiple endpoints 78 
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considered. The low immunogenicity of Rotarix in this adult population is not surprising given the 79 
high baseline immunity observed: all individuals had detectable rotavirus-specific IgA at enrollment, 80 
reflecting the multiple rotavirus exposures that occur throughout life. 81 
The results were more intriguing when considering replication of the vaccine rotavirus. Shedding 82 
in the week after vaccination was more common in vancomycin and broad-spectrum antibody 83 
recipients (8/21 each vs 1/21 in the placebo arm), while the quantity of viral shedding was 84 
significantly higher in vancomycin than placebo recipients. These findings are contrary to previous 85 
findings in mice, where antibiotic treatment decreased shedding but increased antibody response 86 
following subsequent rotavirus exposure (Uchiyama et al., 2014). Nonetheless, if comparable 87 
increases in vaccine shedding were translated to a rotavirus-naive infant population, it is plausible 88 
that this might prompt a corresponding improvement in vaccine-induced immunity. 89 
The study by Harris et al (2018) must be interpreted within the context of several important 90 
caveats. Its study population is far removed from the infant populations at risk of impaired oral 91 
vaccine response, both in terms of baseline microbiota composition and rotavirus exposure history. 92 
During a trial of children in India, a 3-day course of azithromycin induced marked changes in 93 
microbiota composition but did not significantly affect the immunogenicity or shedding of oral 94 
poliovirus vaccine (Grassly et al., 2016). In mice, antibiotic exposure has been shown to deplete total 95 
secretory IgA expression, potentially via its effects on the bacterial microbiota (Ruiz et al., 2017). 96 
This mechanism, as opposed to the observed perturbations in microbiota composition, could 97 
potentially account for the observed differences in rotavirus shedding, further undermining the 98 
relevance of these findings to rotavirus-naive infants. Finally, although the study sought to broadly 99 
recapitulate phenotypes linked with rotavirus response in observational studies, the extent to which 100 
this was achieved is questionable. For example, in Pakistan the mean relative abundance of 101 
Proteobacteria at the time of the first dose was 2.7% in Rotarix responders and 1.7% in non-102 
responders (Harris et al., 2017). In the present study, Proteobacteria were scarce before treatment 103 
but often made up the majority of the bacterial microbiota (>95% in one individual) at the time of 104 
vaccination in vancomycin recipients. Antibiotics remain a blunt tool for reshaping the microbiota. 105 
These caveats notwithstanding, Harris et al (2018) have laid a novel path for translating 106 
observational data into hypothesis-driven intervention. Non-therapeutic antibiotic administration was 107 
used in this study not for its potential real-world application, but as a means of testing whether 108 
targeted microbiota perturbations can elicit changes in vaccine outcome. In the coming years, it will 109 
be important to improve our understanding of the relationship between microbiota composition and 110 
rotavirus vaccine response. We must consider not only whether microbiota composition is 111 
associated with vaccine response, but the strength of this link and the mechanisms that underpin it. 112 
Given the complexity of the microbiota and its significant geographic variability, we should not expect 113 
the emerging narratives to be simple. Meanwhile, our potential to elicit more nuanced changes in 114 
microbiota via prebiotic or probiotic intervention is likely to improve. The extent to which these can 115 
be harnessed to improve rotavirus vaccine response and thereby lessen the global burden of 116 
diarrheal disease remains uncertain, but it is undoubtedly an avenue worthy of exploration. 117 
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